Tuesday, February 08, 2022
Cocrystal Pharma Inc. (COCP)
Drugs For COVID-19 Advance As The Pandemic Won’t Go Away
Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
- Cocrystal Makes Progress Against SARS-CoV-2. In November 2021, the SARS-CoV-2 Omicron variant was identified as a new, highly contagious strain. Although less virulent than other strains, its genetic variations allowed it to evade immune protection from current vaccines. Since then, variants have been identified with genetic sequences showing emergence after the Omicron strain. We believe this highlights the need for new drugs with different mechanisms of action and long-term efficacy.
Cocrystal Has Developed Drugs That Block Viral Reproduction. Cocrystal has been developing drugs that block the RNA protease enzyme needed for viral replication. These are highly conserved proteins that do not vary between strains and can be effective against new variants. This contrasts with the current COVID-19 vaccines that stimulate an immune response against a viral surface marker which can …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
